TP53 and neoplasm: Circulating tumor fraction remained statistically significant in the model (HR = 1.20 per 10% increase in tumor fraction, 95% CI = 1.09 to 1.32; log-rank P < .001), along with TP53 mutation (HR = 1.84, 95% CI = 1.27 to 2.65; log-rank P = .001) and FGFR1 gain (HR = 2.91, 95% CI = 1.61 to 5.25; log-rank P < .001).